KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Net Income (2018 - 2025)

Historic Net Income for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$33.6 million.

  • BioNTech SE's Net Income fell 11542.21% to -$33.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$730.0 million, marking a year-over-year decrease of 69181.54%. This contributed to the annual value of -$710.9 million for FY2024, which is 14582.55% down from last year.
  • As of Q3 2025, BioNTech SE's Net Income stood at -$33.6 million, which was down 11542.21% from -$474.1 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Net Income registered a high of $7.2 billion during Q3 2021, and its lowest value of -$865.6 million during Q2 2024.
  • Its 5-year average for Net Income is $1.9 billion, with a median of $934.5 million in 2023.
  • In the last 5 years, BioNTech SE's Net Income skyrocketed by 163746041825.11% in 2021 and then crashed by 31749.74% in 2024.
  • Quarter analysis of 5 years shows BioNTech SE's Net Income stood at $7.2 billion in 2021, then tumbled by 67.54% to $2.3 billion in 2022, then tumbled by 59.81% to $934.5 million in 2023, then crashed by 70.32% to $277.3 million in 2024, then plummeted by 112.1% to -$33.6 million in 2025.
  • Its Net Income was -$33.6 million in Q3 2025, compared to -$474.1 million in Q2 2025 and -$499.6 million in Q1 2025.